DXB

3.19%

45.5¢ dimerix limited

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

First 586 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

25/09/20

14:34

Post #: 47631126
Share

Originally posted by SteadyEddie: ↑

Thanks for the detailed analysis OvF. As a medico I thought I'd jump in and clarify some things for others.
Facts so far -
In FSGS: Orphan Drug status for DMX- 200 in FSGS was gained in December 2015. The recent FSGS trial results announced 29 July showed that DMX-200 drug works is patients with deteriorating kidney function reducing the rate of albuminuria ( protein loss in the urine) by average 29%. The mechanism of action is thought to be reducing damaging levels of inflammation. The average starting level of proteinuria in this group was 411mg/mmol - remember this number.... If you can reduce proteinuria you can delay / prevent the need to go on dialysis at cost $100,000 per year. Having orphan drug status means potentially you can charge up to about $80,000 per year per patient for DMX-200. Multiply that by the 80,000 patients with FSGS in USA and you get big numbers. The recent diabetic trial doesn't change any of these numbers.
Looking at Diabetic kidney disease (DKD): inclusion criteria same as earlier trials proteinuria >30mg/mmol, overall result not significantly better than placebo. BUT - still positive result in those with more serious disease > 57mg/mmol (18% improvement). In previous studies only patients with much higher levels of proteinuria actually joined the trials but in this study there were a significant proportion with only mild disease. Thus it seems that it works in more serious disease only. This is consistent with the FSGS trial - remember the average 411mg/mmol entry level for patients - much higher than the DKD trial. This is useful information to proceed to the phase 3 trial - patients with mild disease will be excluded. The market is still huge for severe disease. Looking forward to reading the in depth analysis by researchers.

My conclusion - DMX-200 appears to be an effective anti-inflam agent in mod - severe kidney disease - but we still need confirmation with a larger phase 3 trial.

Covid: study yet to start for DMX-700 - similar mechanism of action to reduce excessive inflammation without side effects associated with steroids.

Expand

Hi Steady Eddie,

Thank you, great post! The only thing Dyeman is correct it’s DMX-200 being trialled in COVID-19. DMX-700 is still in pre-clinical, albeit for COPD.

Did you ever go & see Steady Eddie live? He was hilarious, went to his stand up shows a few times. Are you a surgeon, as I could see why you chose that Nic?

DXB Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

ITM

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

STN

Saturn’s stars have aligned for the gold explorer’s Apollo Project

LLL

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

RHI

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

KGL

KGL sniffs 19% Cu from drilling at Rockface play in NT

TVN

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

There are more pages in this discussion • 42 more messages in this thread...

First 586 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 45.5¢		Change -0.015(3.19%)		Mkt cap ! $250.3M

Open	High	Low	Value	Volume
46.5¢	49.0¢	45.5¢	$1.515M	3.232M

Buyers (Bids)

No.	Vol.	Price($)
1	161532	45.5¢

Sellers (Offers)

Price($)	Vol.	No.
46.5¢	33998	2

View Market Depth

No.	Vol.	Price($)
1	161532	0.455
5	65614	0.450
3	20200	0.445
5	123798	0.440
1	100000	0.435

Price($)	Vol.	No.
0.465	10000	1
0.470	21001	1
0.475	6000	1
0.480	2085	1
0.485	61748	3

Last trade - 16.10pm 05/07/2024 (20 minute delay)

DXB (ASX) Chart

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

KGL sniffs 19% Cu from drilling at Rockface play in NT

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

Top Stories

The Big Deal: Free-to-air TV swings the axe, but will it be enough as enormous sports deal bills loom?

Fast-track assaying yields 182 g/t gold for iTech at new NT play

Week 27 Wrap: "Election year" is here as UK Labour win contrasts France; Trump wins immunity & annual report season hushes ASX

Saturn’s stars have aligned for the gold explorer’s Apollo Project

Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng

Red Hill Minerals Signs $6.5 Million Agreement with Peel Mining to Explore Curnamona Project, NSW

Climate change to drive market trends to the moon

KGL sniffs 19% Cu from drilling at Rockface play in NT

Tivan and EARTH AI gear up to commence fresh drilling at Sandover lead-silver project, NT

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News